Amlexanox Enhances Temozolomide-Induced Antitumor Effects in Human Glioblastoma Cells by Inhibiting IKBKE and the Akt-mTOR Signaling Pathway

[Image: see text] Temozolomide (TMZ), as the first-line chemotherapeutic agent for the treatment of glioblastoma multiforme (GBM), often fails to improve the prognosis of GBM patients due to the quick development of resistance. The need for more effective management of GBM is urgent. The aim of this...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ACS Omega
Main Authors: Xiong, Jinbiao, Guo, Gaochao, Guo, Lianmei, Wang, Zengguang, Chen, Zhijuan, Nan, Yang, Cao, Yiyao, Li, Ruilong, Yang, Xuejun, Dong, Jun, Jin, Xun, Yang, Weidong, Huang, Qiang
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2021
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7906592/
https://ncbi.nlm.nih.gov/pubmed/33644550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsomega.0c05399
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados